Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07158918 · ClinicalTrials.gov registry record · Phase 1

ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors

A Phase 1 study of Solid Tumors, sponsored by ABL Bio.

Recruiting
Registry status
Phase 1
Development phase
65
Enrollment target
6
Study locations

NCT07158918 is a Phase 1 study of Solid Tumors that is actively recruiting participants, run by ABL Bio. The registered enrollment target is 65 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (77% lower). The trial reports 6 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07158918, a Phase 1 study of Solid Tumors, is actively recruiting participants, sponsored by ABL Bio.

RECRUITING
Registry status
Phase 1
Development phase
65 participants
Enrollment target
6
Study locations

Study Summary

This study is to assess the safety and antitumor activity of ABL103 plus pembrolizumab, with or without taxane, in advanced or metastatic solid tumors.

Conditions Studied

Solid Tumors

Interventions

  • DRUG KEYTRUDA® (pembrolizumab)
  • DRUG ABL103
  • DRUG Taxane

Study Locations (6)

Other

  • Seoul National University Bundang Hospital - Seongnam
  • Seoul National University Hospital - Seoul
  • Asan Medical Center - Seoul
  • Samsung Medical Center - Seoul

Ohio

  • UH Cleveland Medical Center - Cleveland

Victoria

  • PASO Medical - Frankston

Trial Details

FieldValue
Enrollment Target 65 participants
Start Date 2025-08-06
Est. Completion 2027-12-02
Phase Phase 1

Sponsor

ABL Bio

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07158918

The ClinicalTrials.gov registry entry for NCT07158918 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (77% lower). The listed sponsor is ABL Bio, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 3 interventions - of which KEYTRUDA® (pembrolizumab) is the first listed.

NCT07158918 reports 6 study locations spanning 3 distinct geographic areas - top geographies include Other, Ohio, Victoria.

Frequently Asked Questions

What is clinical trial NCT07158918 about?

NCT07158918 is a clinical study titled "ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors". This study is to assess the safety and antitumor activity of ABL103 plus pembrolizumab, with or without taxane, in advanced or metastatic solid tumors.

What is the current status of trial NCT07158918?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2025-08-06. Estimated completion is 2027-12-02.

What conditions does trial NCT07158918 study?

This clinical trial studies the following conditions: Solid Tumors.

What interventions are being tested in trial NCT07158918?

The interventions under investigation include: KEYTRUDA® (pembrolizumab) (DRUG), ABL103 (DRUG), Taxane (DRUG).

Who is sponsoring clinical trial NCT07158918?

This trial is sponsored by ABL Bio, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07158918 being conducted?

This trial has 6 study locations across Ohio, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumors

All registered trials for this condition

Ohio

All trials with a study site in Ohio

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.